MCID: BRD004
MIFTS: 51

Borderline Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

MalaCards integrated aliases for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 77 56 45 15 74

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD9CM 36 301.83
MeSH 45 D001883
NCIt 51 C92633
SNOMED-CT 69 20010003
ICD10 34 F60.3
UMLS 74 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to alexithymia and bipolar disorder. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Peptide ligand-binding receptors and cAMP signaling pathway. The drugs Citalopram and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and cortex, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 77 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder (EUPD),... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 alexithymia 30.8 COMT HTR1A SLC6A4
2 bipolar disorder 30.5 BDNF COMT HTR1A HTR2A SLC6A4 TPH1
3 eating disorder 30.5 BDNF COMT HTR2C SLC6A4
4 antisocial personality disorder 30.3 COMT HTR1B MAOA SLC6A4
5 dysthymic disorder 30.3 HTR2A MAOA SLC6A4
6 substance dependence 30.2 BDNF HTR1B MAOA SLC6A4
7 conduct disorder 30.2 COMT MAOA SLC6A4 TPH1
8 bulimia nervosa 30.2 BDNF COMT HTR1B HTR2A SLC6A4
9 schizophreniform disorder 30.2 COMT PRL
10 atypical depressive disorder 30.2 HTR2A MAOA SLC6A4
11 pain - chronic 30.1 COMT NR3C1
12 anorexia nervosa 30.1 BDNF COMT HTR2A PRL SLC6A4
13 alcohol abuse 30.1 BDNF HTR2A PRL SLC6A4
14 traumatic brain injury 30.1 BDNF COMT
15 avoidant personality disorder 30.0 MAOA SLC6A4 TPH1
16 oppositional defiant disorder 30.0 COMT MAOA SLC6A4
17 intermittent explosive disorder 30.0 HTR1A PRL SLC6A4
18 personality disorder 30.0 AVPR1A BDNF COMT HTR1A HTR1B HTR2A
19 substance abuse 29.9 BDNF COMT HTR1B MAOA PRL SLC6A4
20 schizoaffective disorder 29.9 BDNF COMT HTR2A PRL SLC6A4
21 disease of mental health 29.8 BDNF COMT HTR1A HTR2A HTR2C MAOA
22 social phobia 29.8 HTR1A MAOA PRL SLC6A4
23 fibromyalgia 29.8 COMT HTR2A PRL SLC6A4
24 panic disorder 29.6 COMT HTR1A HTR2A MAOA SLC6A4
25 amnestic disorder 29.6 BDNF HTR1A
26 depression 29.6 BDNF HTR1A HTR2A HTR2C MAOA NR3C1
27 attention deficit-hyperactivity disorder 29.2 BDNF COMT HTR1A HTR1B HTR2A HTR2C
28 bipolar i disorder 29.2 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
29 post-traumatic stress disorder 28.9 BDNF COMT FKBP5 HTR2A MAOA NR3C1
30 generalized anxiety disorder 28.9 BDNF COMT HTR1A HTR2A MAOA SLC6A4
31 schizophrenia 28.8 BDNF COMT HTR1A HTR1B HTR2A HTR2C
32 anxiety 28.7 BDNF COMT HTR1A HTR2A HTR2C MAOA
33 psychotic disorder 28.7 BDNF COMT HTR1A HTR2A HTR2C PRL
34 chronic fatigue syndrome 28.7 COMT HTR1A HTR2A MAOA NR3C1 SLC6A4
35 endogenous depression 28.4 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
36 obsessive-compulsive disorder 28.3 BDNF COMT HTR1A HTR1B HTR2A HTR2C
37 mood disorder 28.2 BDNF COMT HTR1A HTR1B HTR2A HTR2C
38 mental depression 28.0 BDNF COMT FKBP5 HTR1A HTR2A HTR2C
39 alcohol dependence 28.0 BDNF COMT HTR1A HTR1B HTR2A HTR2C
40 major depressive disorder 27.6 BDNF COMT FKBP5 HTR1A HTR1B HTR2A
41 multiple personality disorder 11.4
42 impulse control disorder 11.1
43 pol iii-related leukodystrophies 10.6
44 bronchopulmonary dysplasia 10.6
45 cognitive function 1, social 10.4
46 mammographic density 10.3 COMT PRL
47 phobia, specific 10.3 COMT MAOA
48 alcoholic psychosis 10.2 HTR2A SLC6A4
49 early-onset schizophrenia 10.2 BDNF HTR2A
50 tardive dyskinesia 10.2 COMT HTR2A

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

MGI Mouse Phenotypes related to Borderline Personality Disorder:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 AVPR1A BDNF COMT FKBP5 HTR1A HTR1B
2 homeostasis/metabolism MP:0005376 10 AVPR1A BDNF COMT FKBP5 HTR1A HTR2C
3 cardiovascular system MP:0005385 9.97 AVPR1A COMT HTR1A HTR1B MAOA NR3C1
4 endocrine/exocrine gland MP:0005379 9.92 AVPR1A BDNF COMT HTR1B HTR2A NR3C1
5 integument MP:0010771 9.63 BDNF HTR2C NR3C1 PRL SLC6A4 TPH1
6 muscle MP:0005369 9.5 AVPR1A HTR1B HTR2A HTR2C NR3C1 SLC6A4
7 nervous system MP:0003631 9.28 AVPR1A BDNF COMT HTR1A HTR2C MAOA

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 2,Not Applicable 59729-33-8 2771
2
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
3
Dopamine Approved Phase 4,Phase 2,Not Applicable 62-31-7, 51-61-6 681
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
7 Omega 3 Fatty Acid Phase 4
8 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
9 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
11 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
14 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
15 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Not Applicable
16 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
18 Muscarinic Antagonists Phase 4,Phase 2,Not Applicable
19 Parasympatholytics Phase 4,Phase 2,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Antiparkinson Agents Phase 4,Phase 2,Not Applicable
23 Cholinergic Agents Phase 4,Phase 2,Not Applicable
24 Cholinergic Antagonists Phase 4,Phase 2,Not Applicable
25 Serotonin Antagonists Phase 4,Phase 2,Not Applicable
26 Dopamine Agents Phase 4,Phase 2,Not Applicable
27 Dopamine Antagonists Phase 4,Phase 2,Not Applicable
28 Diuretics, Potassium Sparing Phase 4
29 Anticonvulsants Phase 4,Phase 3,Not Applicable
30 Calcium, Dietary Phase 4
31 Hormones Phase 4,Phase 2,Not Applicable
32 Sodium Channel Blockers Phase 4
33 calcium channel blockers Phase 4
34 Cytochrome P-450 Enzyme Inhibitors Phase 4
35 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
36
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
37
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
38
Ethanol Approved Phase 3,Phase 2,Not Applicable 64-17-5 702
39
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
40
Olanzapine Approved, Investigational Phase 3,Not Applicable 132539-06-1 4585
41 Narcotic Antagonists Phase 3,Phase 2,Not Applicable
42 Narcotics Phase 3,Phase 2,Not Applicable
43 Quetiapine Fumarate Phase 3,Phase 2 111974-72-2
44 Antiemetics Phase 3,Not Applicable
45 Gastrointestinal Agents Phase 3,Not Applicable
46 Analgesics, Opioid Phase 3,Not Applicable
47 Anti-Infective Agents Phase 3,Phase 2,Phase 1
48 Anti-Infective Agents, Local Phase 3,Phase 2
49
Acetaminophen Approved Phase 2 103-90-2 1983
50
Ziprasidone Approved Phase 2 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 165)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
3 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
4 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
5 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
6 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
7 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
8 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
9 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
10 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
11 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3 Olanzapine;placebo
12 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder Completed NCT00088036 Phase 3 Olanzapine
13 The Short-Term MBT Project Recruiting NCT03677037 Phase 3
14 Naltrexone in Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
15 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
16 Acetaminophen and Social Processes Unknown status NCT02108990 Phase 2 Acetaminophen
17 Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment Completed NCT02125942 Phase 1, Phase 2
18 Ziprasidone in the Treatment of Borderline Personality Disorder Completed NCT00635921 Phase 2 ziprasidone;Placebo
19 Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Completed NCT01103180 Phase 2 Escitalopram
20 Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
21 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
22 Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder Completed NCT00145678 Phase 2
23 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
24 Treatment of Suicidal Women With Borderline Personality Disorder Completed NCT00183651 Phase 2
25 Oxytocin as Adjunctive Therapy for Schizophrenia Completed NCT01699997 Phase 2 Oxytocin;Placebo
26 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
27 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
28 Brexpiprazole in Borderline Personality Disorder Recruiting NCT03418675 Phase 2 Rexulti;Placebo
29 A Novel Drug for Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
30 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Recruiting NCT02728778 Phase 2 incobotulinumtoxin A
31 Ketamine in Borderline Personality Disorder Recruiting NCT03395314 Phase 2 Ketamine;Midazolam
32 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
33 Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder Not yet recruiting NCT03209102 Phase 2
34 Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Terminated NCT01212588 Phase 2 mifepristone;Placebo
35 N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
36 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
37 Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder Unknown status NCT00269139 Phase 1
38 20 Weeks DBT Group Skills Training Study Completed NCT01193205 Phase 1
39 Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents Completed NCT01111734 Phase 1 fMRI
40 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
41 Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Unknown status NCT01602497 Not Applicable
42 Event Related Potentials in Borderline Personality Disorder and Major Depression Unknown status NCT01469663
43 Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive Intervention Unknown status NCT01531634 Not Applicable
44 Guanfacine to Treat Borderline Personality Disorder Unknown status NCT00358969 Not Applicable guanfacine (Tenex)
45 A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder Unknown status NCT01033708 Not Applicable
46 Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder Unknown status NCT00131781 Not Applicable
47 A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults Unknown status NCT01426984 Not Applicable methylphenidate
48 DBT in Borderline Personality Disorder Unknown status NCT00252031 Not Applicable
49 DBT and Escitalopram in Borderline Personality Disorder Unknown status NCT00255554 Not Applicable Escitalopram
50 Methylation Status of BDNF Gene After Dialectical Behavior Therapy in BPD Unknown status NCT02134223 Not Applicable

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

42
Brain, Amygdala, Cortex, Testes, Pituitary, Prefrontal Cortex, Eye

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 3026)
# Title Authors Year
1
Longitudinal associations among primary and secondary psychopathic traits, anxiety, and borderline personality disorder features across adolescence. ( 30628800 )
2019
2
Rejection Sensitivity and Borderline Personality Disorder Features: The Mediating Roles of Attachment Anxiety, Need to Belong, and Self-Criticism. ( 30650007 )
2019
3
Violent Offending in Borderline Personality Disorder and Attention Deficit/ Hyperactivity Disorder. ( 30844407 )
2019
4
Dimensions of Impulsivity in Healthy People, Patients with Borderline Personality Disorder, and Patients with Attention-Deficit/Hyperactivity Disorder. ( 30628513 )
2019
5
Impulsivity and its association with childhood trauma experiences across bipolar disorder, attention deficit hyperactivity disorder and borderline personality disorder. ( 30336349 )
2019
6
Effect of negative valence on assessment of self-relevance in female patients with borderline personality disorder. ( 30629628 )
2019
7
Repetitive Transcranial Magnetic Stimulation in the Treatment of a Difficult to Treat Condition, Borderline Personality Disorder. ( 30633728 )
2019
8
Trustworthiness appraisal deficits in borderline personality disorder are associated with prefrontal cortex, not amygdala, impairment. ( 30639176 )
2019
9
Crying in borderline personality disorder patients. ( 30640050 )
2019
10
Longitudinal development of risk-taking and self-injurious behavior in association with late adolescent borderline personality disorder symptoms. ( 30641342 )
2019
11
The Role of Interactional Agreeableness in Responsive Treatments for Patients With Borderline Personality Disorder. ( 30650009 )
2019
12
Interdiagnostician Reliability of the DSM-5 Section II and Section III Alternative Model Criteria for Borderline Personality Disorder. ( 30650010 )
2019
13
The Relationship Among Shame, Nonsuicidal Self-Injury, and Suicidal Behaviors in Borderline Personality Disorder. ( 30654709 )
2019
14
Preliminary Validation of the Interpersonal Dysphoria Model of Borderline Personality Disorder. ( 30665228 )
2019
15
The role of attachment characteristics in dialectical behavior therapy for patients with borderline personality disorder. ( 30667573 )
2019
16
Changes in mindfulness facets in a dialectical behaviour therapy skills training group program for borderline personality disorder. ( 30672590 )
2019
17
Exploring the boundaries between borderline personality disorder and suicidal behavior disorder. ( 30673835 )
2019
18
Effects of transcranial direct current stimulation on the cognitive control of negative stimuli in borderline personality disorder. ( 30674987 )
2019
19
Collaborative Deprescribing in Borderline Personality Disorder: A Narrative Review. ( 30676404 )
2019
20
Impact of comorbid borderline personality disorder on inpatient treatment for bulimia nervosa: analysis of routine data. ( 30680217 )
2019
21
Influence of betrayal trauma on borderline personality disorder traits. ( 30681038 )
2019
22
Deaths by Suicide and Other Causes Among Patients With Borderline Personality Disorder and Personality-Disordered Comparison Subjects Over 24 Years of Prospective Follow-Up. ( 30688417 )
2019
23
Altered Oscillatory Responses to Feedback in Borderline Personality Disorder are Linked to Symptom Severity. ( 30689144 )
2019
24
Aripiprazole compared with placebo for auditory verbal hallucinations in youth with borderline personality disorder: Protocol for the VERBATIM randomized controlled trial. ( 30689305 )
2019
25
Relations of Maternal Borderline Personality Disorder Features With Preschooler Executive Functioning and Theory of Mind. ( 30689501 )
2019
26
Women With Borderline Personality Disorder Show Reduced Identification of Emotional Facial Expressions and a Heightened Negativity Bias. ( 30689504 )
2019
27
Biased Attention to Facial Expressions of Ambiguous Emotions in Borderline Personality Disorder: An Eye-Tracking Study. ( 30689505 )
2019
28
The Therapeutic Alliance Over 10 Sessions of Therapy for Borderline Personality Disorder: Agreement and Congruence Analysis and Relation to Outcome. ( 30689513 )
2019
29
Mentalizing Based on External Features in Borderline Personality Disorder Compared With Healthy Controls: The Role of Attachment Dimensions and Childhood Trauma. ( 30689514 )
2019
30
Number of Borderline Personality Disorder Criteria and Depression Predict Poor Functioning and Quality of Life in Outpatient Youth. ( 30689518 )
2019
31
FKBP5 gene variants and borderline personality disorder. ( 30711865 )
2019
32
Hallucinations in patients with borderline personality disorder: characteristics, severity and relationship with schizotypy and loneliness. ( 30712290 )
2019
33
Metacognitive improvement and symptom change in a 3-month treatment for borderline personality disorder. ( 30712326 )
2019
34
Emotions at the border: Increased punishment behavior during fair interpersonal exchanges in borderline personality disorder. ( 30714797 )
2019
35
Differentiating bipolar disorder from borderline personality disorder: Diagnostic accuracy of the difficulty in emotion regulation scale and personality inventory for DSM-5. ( 30699870 )
2019
36
Screening for Borderline Personality Disorder in Psychiatric Outpatients With Major Depressive Disorder and Bipolar Disorder. ( 30677270 )
2019
37
Bipolar Disorder and Comorbid Borderline Personality Disorder: Patient Characteristics and Outcomes in US Hospitals. ( 30646620 )
2019
38
Common and distinct patterns of grey matter alterations in borderline personality disorder and bipolar disorder: voxel-based meta-analysis. ( 30846010 )
2019
39
Optimizing borderline personality disorder treatment by incorporating significant others: A review and synthesis. ( 30714800 )
2019
40
Emotional Responsiveness in Borderline Personality Disorder: The Role of Basal Hyperarousal and Self-Reported Emotional Regulation. ( 30720601 )
2019
41
Neuropsychological findings in recent onset schizophrenia and borderline personality disorder: a comparison study. ( 30724326 )
2019
42
Parenting in Patients with Borderline Personality Disorder, Sequelae for the Offspring and Approaches to Treatment and Prevention. ( 30729325 )
2019
43
Borderline Personality Disorder Symptom Comorbidity Within a High Externalizing Sample: Relationship to the Internalizing-Externalizing Dimensional Structure of Psychopathology. ( 30730780 )
2019
44
Prescribing Practices for Patients With Borderline Personality Disorder During Psychiatric Hospitalizations. ( 30742548 )
2019
45
The Experience of Maltreatment in Young Children Whose Mothers Have Borderline Personality Disorder: Reflections in Their Narrative Representations. ( 30742556 )
2019
46
Does a history of childhood abuse moderate the association between symptoms of posttraumatic stress disorder and borderline personality disorder in survivors of intimate partner violence? ( 30742703 )
2019
47
Residential eating disorder outcomes associated with screening positive for substance use disorder and borderline personality disorder. ( 30746736 )
2019
48
Early maladaptive schemas and borderline personality disorder features in a non-clinical sample: A network analysis. ( 30771229 )
2019
49
Response inhibition in borderline personality disorder: neural and behavioral correlates. ( 30772405 )
2019
50
The effectiveness of individual schema therapy in older adults with borderline personality disorder: Protocol of a multiple-baseline study. ( 30775612 )
2019

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.26 AVPR1A HTR1A HTR1B HTR2A HTR2C NR3C1
2 12.03 BDNF HTR1A HTR1B
3 11.96 AVPR1A HTR2A HTR2C
4 11.91 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
5
Show member pathways
11.66 HTR1A HTR1B HTR2A HTR2C
6 11.56 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
7 11.49 FKBP5 NR3C1 PRL
8
Show member pathways
10.96 COMT MAOA SLC6A4
9 10.8 HTR2A HTR2C
10
Show member pathways
10.78 COMT MAOA TPH1
11
Show member pathways
10.65 COMT MAOA
12 10.61 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
13 10.6 COMT MAOA

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.73 AVPR1A HTR1A HTR1B HTR2A HTR2C SLC6A4
2 integral component of presynaptic membrane GO:0099056 9.33 HTR1B HTR2A SLC6A4
3 dendrite GO:0030425 9.1 BDNF COMT HTR1A HTR1B HTR2A HTR2C
4 serotonergic synapse GO:0099154 8.96 HTR1B SLC6A4

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 AVPR1A HTR1A HTR2A PRL
2 chemical synaptic transmission GO:0007268 9.83 HTR1A HTR1B HTR2A HTR2C
3 memory GO:0007613 9.72 BDNF HTR2A SLC6A4
4 positive regulation of fat cell differentiation GO:0045600 9.67 HTR2A HTR2C TPH1
5 feeding behavior GO:0007631 9.62 HTR1B HTR2C
6 regulation of dopamine secretion GO:0014059 9.62 HTR1B HTR2A
7 behavioral fear response GO:0001662 9.61 HTR1A HTR2C
8 positive regulation of vasoconstriction GO:0045907 9.61 AVPR1A HTR2A
9 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.61 HTR1A HTR1B HTR2A
10 bone remodeling GO:0046849 9.6 HTR1B TPH1
11 circadian rhythm GO:0007623 9.59 SLC6A4 TPH1
12 catecholamine metabolic process GO:0006584 9.58 COMT MAOA
13 neurotransmitter catabolic process GO:0042135 9.58 COMT MAOA
14 regulation of behavior GO:0050795 9.57 HTR1A HTR1B
15 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.56 HTR1B HTR2A
16 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.56 HTR1A HTR1B HTR2A HTR2C
17 dopamine catabolic process GO:0042420 9.54 COMT MAOA
18 activation of phospholipase C activity GO:0007202 9.54 AVPR1A BDNF HTR2A
19 sperm ejaculation GO:0042713 9.51 AVPR1A SLC6A4
20 vasoconstriction GO:0042310 9.5 HTR1A HTR1B SLC6A4
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.48 HTR2A HTR2C
22 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.46 HTR1A HTR1B
23 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.4 HTR2A HTR2C
24 response to drug GO:0042493 9.35 COMT HTR1B HTR2A HTR2C SLC6A4
25 serotonin receptor signaling pathway GO:0007210 9.33 HTR1A HTR2A HTR2C
26 behavior GO:0007610 8.92 HTR1A HTR1B HTR2A HTR2C
27 signal transduction GO:0007165 10.11 AVPR1A HTR1A HTR1B HTR2A HTR2C NR3C1
28 G protein-coupled receptor signaling pathway GO:0007186 10.04 AVPR1A HTR1A HTR1B HTR2A HTR2C

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.77 AVPR1A HTR1A HTR1B HTR2A HTR2C
2 drug binding GO:0008144 9.5 HTR1B HTR2A HTR2C
3 neurotransmitter receptor activity GO:0030594 9.46 HTR1A HTR1B HTR2A HTR2C
4 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.26 HTR2A HTR2C
5 G protein-coupled serotonin receptor activity GO:0004993 9.26 HTR1A HTR1B HTR2A HTR2C
6 serotonin binding GO:0051378 9.02 HTR1A HTR1B HTR2A HTR2C SLC6A4

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....